| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec0024795f45a646ef64b3664ab8a26d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6489
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate |
2005-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f22c9a72b1b961b93b365790e38ce231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d12f9f36780422e53884c17ea62d785a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffd10df8b287c2bccb433ddca33faafc |
| publicationDate |
2007-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1773879-A1 |
| titleOfInvention |
Inhibitors of l1 and adam10 for the treatment of carcinomas |
| abstract |
Described is a pharmaceutical composition comprising a compound (s) interfering with the biological activity of L1 and/or ADAM10 or their expression. Also described is the use of said compound (s) for the prevention/treatment of carcinomas like ovarian and endometrial carcinoma. Finally, the diagnosis of highly malignant forms of carcinomas which is based on the determination of the activity/expression of L1 and/or ADAM10 is described. |
| priorityDate |
2004-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |